Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Emgality
Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
